Gov. Jay Nixon announced a plan to support the building of a new, state-of-the-art facility in Chesterfield to be leased by Pfizer Inc., one of the world’s premier biopharmaceutical companies. Pfizer has been in Missouri for more than 13 years and currently employs more than 450 scientists and other professionals in the state.
The company expects to create more than 80 new jobs through the Chesterfield project over the next few years. To support Pfizer’s new facility, the state has offered a strategic economic incentive package that the company can receive if it meets strict job creation criteria. The expansion is also being made possible through local incentives offered by St. Louis County.
Construction of the $200 million facility is expected to begin in mid-2017 and be completed by 2020. St. Louis-based CRG, together with Clayco, will be the developer and owner of the new facility in Chesterfield.
Once the new building in Chesterfield is complete, Pfizer will bring together colleagues from two sites and multiple buildings under one roof to house its bioprocess, analytical and formulation development, non-GMP processing, as well as GMP cell banking operations and cell bank storage necessary to support both its R&D and commercial biologic and vaccine products.
“Missouri is an important part of Pfizer’s R&D network, and we’re proud of the world-class employee base we’ve built here,” said John Ludwig, senior vice president of BioTherapeutics Research for Pfizer. “Thanks to the support we’ve received from the state of Missouri, St. Louis County and Chesterfield, our new St. Louis laboratory facility will provide the right location and space as we continue to evolve our business over the coming years.”